Disrupting tumor resistance through therapy targeting depletion of cancer stem cells in head and neck cancer

• Grant number: 16/05710-4
• Support Opportunities: Research Projects - Thematic Grants
• Start date: November 01, 2018
• End date: October 31, 2024
• Field of knowledge: Health Sciences - Dentistry
• Principal Investigator: Pablo Agustin Vargas
• Grantee: Pablo Agustin Vargas
• Host Institution: Faculdade de Odontologia de Piracicaba (FOP). Universidade Estadual de Campinas (UNICAMP). Piracicaba , SP, Brazil
• Associated researchers: Alan Roger dos Santos Silva ; Cristiane Helena Squarize ; Fátima Solange Pasini ; Gilberto de Castro Junior ; Luan César da Silva ; Luiz Paulo Kowalski ; Manoela Domingues Martins ; Marcio Ajudarte Lopes ; Marco Antonio Trevizani Martins ; Rogerio Moraes Castilho ; Sebastião Silvério de Sousa Neto ; Vivian Petersen Wagner
• Associated scholarship(s): 23/13797-6 - TARGETED CHEMOTHERAPY STRATEGIES FOR THE ELIMINATION OF TUMOR STEM CELLS IN YOUNG PATIENTS WITH ORAL SQUAMOUS CELL CARCINOMA, BP.DR; 23/18088-3 - Science on Screen: New Paths for the Treatment of Oral Cancer, BP.JC; 19/06597-5 - Disrupting tumor resistance through therapy targeting depletion of cancer stem cells in Salivary Mucoepidermoid Carcinomas, BP.DR; 19/21898-1 - DISRUPTING TUMOR RESISTANCE THROUGH THERAPY TARGETING DEPLETION OF CANCER STEM CELLS IN HEAD AND NECK CANCER, BP.PD; 19/14139-7 - Disrupting tumor resistance through therapy targeting depletion of cancer stem cells in head and neck cancer, BP.IC

Abstract

Head and Neck Squamous Cell Carcinomas (HNSCCs) represent one of the 6 most common Cancers worldwide. Among different therapeutic approaches, the use of chemotherapy alone or in association with radiotherapy or surgery has proven beneficial to the overall patient survival. Nonetheless, when compared to other Cancers like Leukemia and Hodgkin's disease, the benefits of chemotherapy for Head and Neck Cancer patients remain limited, mainly due to the development of chemoresistance. We have shown that the development of tumor resistance phenotype is mainly driven by (i) epigenetic modifications (e.g.: histone acetylation); (ii) activation of the NFkB signaling; (iii) and the presence of Cancer Stem Cells (CSCs). Our previous findings indicate that the activation of the NFkB signaling pathway is mediated by the deacetylation of tumor histones and the enrichment of the population of CSCs. Further, we found that pharmacological acetylation of tumor histones result in the depletion of CSCs. Once that histone acetylation regulates gene transcription related to the maintenance of CSCs and NFkB signaling, we propose the development of a new therapeutic approach for HNSCC using histone deacetylase inhibitors (HDACi) (Epi-drugs) in combination with pharmacological inhibition of IkB± phosphorylation (NFkB super-repressor). We anticipate that our novel therapeutic approach will disrupt the tumor resistance to cisplatin, the most common chemotherapeutic agent used in the treatment of HNSCC. Of note, targeted inhibition of IkB± phosphorylation results in selective down-regulation of NFkB independently from the off-target effects observed during administration of the NFkB inhibitors Bortezomib and Velcade. Our approach proposes the use of low doses of Emetine; an FDA-approved drug used in the treatment of amoebiasis. This proposal encompasses the collaboration of the University of Campinas (UNICAMP), The Federal University of Rio Grande do Sul (UFRGS), and the University of Michigan (UMICH), and is divided into 3 aims. First aim will (i) determine the therapeutic efficacy of HDAC and IkB± inhibition in the depletion of CSCs and sensitization of HNSCC cell lines to cisplatin; (ii) therapeutic efficiency of HDACi (SAHA®) and IkB± inhibitor (Emetine®) in HNSCC xenografts following by ChIP Seq analysis; (iii) construction of TMAs using PDX tumor samples treated with SAHA® and Emetine® following by the characterization of the epigenetic profile of tumors. Altogether, our proposal will investigate unknown issues associated with the epigenetic control of CSCs, along the validation of a novel therapeutic approach to reduce chemoresistance of HNSCC. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

SILVA, LUAN CESAR; BORGATO, GABRIELL BONIFACIO; WAGNER, VIVIAN PETERSEN; MARTINS, MANOELA DOMINGUES; SANTOS-SILVA, ALAN ROGER; DE CASTRO JR, GILBERTO; KOWALSKI, LUIZ PAULO; SQUARIZE, CRISTIANE HELENA; VARGAS, PABLO AGUSTIN; CASTILHO, ROGERIO MORAES. Repurposing NF kappa B and HDAC inhibitors to individually target cancer stem cells and non-cancer stem cells from mucoepidermoid carcinomas. AMERICAN JOURNAL OF CANCER RESEARCH, v. 13, n. 4, p. 13-pg., 2023-01-01. (19/06597-5, 16/05710-4)

WAGNER, VIVIAN PETERSEN; FERRAROTTO, RENATA; VARGAS, PABLO AGUSTIN; MARTINS, MANOELA DOMINGUES; BINGLE, COLIN D.; BINGLE, LYNNE. Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, v. 181, p. 12-pg., 2023-01-01. (16/05710-4)

SILVA, LUAN CESAR; BORGATO, GABRIELL BONIFACIO; WAGNER, VIVIAN PETERSEN; MARTINS, MANOELA DOMINGUES; ROCHA, GUILHERME ZWEIG; LOPES, MARCIO AJUDARTE; SANTOS-SILVA, ALAN ROGER; DE CASTRO JUNIOR, GILBERTO; KOWALSKI, LUIZ PAULO; NOR, JACQUES E.; et al. Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells. JOURNAL OF ORAL PATHOLOGY & MEDICINE, OCT 2021. (19/06597-5, 16/05710-4, 16/21785-4)